Cure8 news brief
A new Phase 2 study of StemSmart™ could expand treatment options for patients with refractory or fistulising Crohn’s disease if later trials confirm safety and benefit. Appointment of a CRO is an early but important step toward starting the study in Australia and the US.
Patients with treatment‑resistant or fistulising Crohn’s disease, caregivers, clinicians who treat complex IBD, and researchers monitoring stem‑cell–based therapies and clinical trial opportunities.
NeuroScientific has appointed Southern Star Research to support site selection, investigator engagement, logistics, and site management for a planned Phase 2 StemSmart™ trial in refractory (treatment‑resistant) and/or fistulising Crohn’s disease, aiming to start by end of CY2026.
The therapy is a donor bone marrow–derived mesenchymal stem cell product intended to modulate immune responses; the company is also advancing manufacturing scale‑up and contracting data and safety management providers. This item is an operational update focused on trial preparation and partnerships rather than new clinical results.
It notes prior Phase 2 signals referenced by the company but does not provide detailed efficacy or safety data here.
If you follow clinical research in IBD, watch for future announcements about trial registration details, site locations, eligibility criteria, and any posted protocols or investigator brochures before drawing conclusions about effectiveness or availability.
This article is a company press‑style business update about trial preparations; it does not report new trial results. StemSmart™ is an investigational mesenchymal stem cell therapy and is not an approved Crohn’s disease treatment. Outcomes from the planned Phase 2 trial are needed to evaluate safety and efficacy. SummaryConfidence is medium.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This article reports an investigational stem cell therapy (StemSmart MSCs) showing safety and clinical responses in a small group of patients with fistulising Crohn’s disease — a serious complication that’s often hard to...
This trial tests a novel cell-derived extracellular vesicle therapy (DB-3Q) for people with Crohn’s disease who have not responded to standard advanced therapies. It may offer a different biologic approach if proven safe...
Shattuck Labs plans to advance a DR3-targeting bispecific antibody (SL-325) into a Phase 2b trial for Crohn's disease, which is relevant to people watching new investigational biologics for IBD. The report is a...
